ArticleFrontiers in immunology2026
Miltirone promotes pyroptosis via increasing pyroptosis-related protein NLRP3 and AIM2 in kidney renal clear cell carcinoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pyroptosis, a type of programmed cell death, exerts direct influence on inflammatory processes and immune response. A previous study suggests that miltirone exhibits notable anti-tumor activities and has been shown to induce tumor cell pyroptosis. Nevertheless, the therapeutic value of miltirone in kidney renal clear cell carcinoma (KIRC) remains underexplored. Methods and results: Using TCGA pan-cancer data, we uncovered widely expressed pyroptosis-related genes (NLRP3 and AIM2). Mechanistically, the genomic amplification alteration and high CNV percentages in pan-cancer induced an abnormal expression. StromalScore analysis suggested that NLRP3 and AIM2 were activated by the tumor immune microenvironment in KIRC. Enrichment analysis indicated that NLRP3 and AIM2 regulated the inflammatory response and were related to immune infiltration in KIRC. Furthermore, Kaplan-Meier curve and ROC analysis indicated that a high expression of AIM2 was associated with a worse prognosis of KIRC patients. MTT assays and flow cytometry revealed that miltirone treatment induced KIRC cell pyroptosis and inhibited cell proliferation, with changes in the expression level of NLPR3, AIM2, caspase-3, and GSDMD. The enhancement of cell pyroptosis and the release of IL-1β and IL-18 cytokines were reversed by pretreatment with the pyroptosis inhibitor VX-765. Conclusions: Our study revealed the prognostic value of NLRP3 and AIM2 in KIRC. Miltirone treatment inhibited KIRC cell proliferation and enhanced cell pyroptosis via the NLRP3/AIM2/GSDMD axis. This study provides a novel molecular mechanism and potential therapeutic targets in KIRC progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.